Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synvisc plus usual care versus usual care for knee osteoarthritis
2008-005814-28Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Sep 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sodium hyaluronate in knee osteoarthritis (OA) (2 arms), sponsored by Erasmus MC. Primary endpoint: OMERACT-OARSI responder rate at 12 months. Started Sep 2008; status: active.
02
Drugs
sodium hyaluronate
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2008-005814-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005814-28.